NHS criteria and how they are applied in practice — setting out what I have, and where I think it stops being reliable.
I was wrong about NHS criteria in a thread last spring and I would like to correct it publicly rather than quietly.
The error was in the units, which changed the conclusion by an order of magnitude. Setting out the corrected version, and the way I now check for that class of mistake.
Thank you for taking the time. That was more work than a reply usually is.
Adding the measurement that post #3 says would settle it.
Pharmacy practice varies between pharmacies and is not deducible from the regulatory position. Two people can honestly report opposite experiences.
One case, stated as one case.
NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.
Worth reading the earlier posts in this thread before acting on mine.
NHS criteria came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
I read the earlier replies on NHS criteria twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
Grateful for the specificity. Vague answers to this question are what sent me looking.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
Someone should write this up properly, and it should probably not be me.
Adding the measurement that post #8 says would settle it.
Where a service has its own criteria layered on top of national guidance, those are the criteria that decide the outcome, and they are usually published.
Stating my assumptions rather than smuggling them in.
Practical answer on NHS criteria, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.
Agreed on all of that, and I have nothing to add to it.
Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.
This is where my knowledge stops and I would rather mark the edge than blur it.
Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.
Coming back to post #14, because the follow-up matters more than the original answer.
NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.
Same experience here, different supplier, so it is at least not unique to one of them.
Answering the question post #19 raises rather than the one it answers.
I have three months of notes on NHS criteria and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
Correcting an out-of-date claim in this subcategory with a source and a date is more valuable than a new topic on the same question.
Worth saying I have only my own numbers here, and n is small.
Post #23 is the version of this I will quote in future. One addition.
Where a service has its own criteria layered on top of national guidance, those are the criteria that decide the outcome, and they are usually published.
The documentation on NHS criteria is better than this thread and I say that as someone who has posted in the thread.
I had written a reply contradicting post #23 and deleted it. Here is what survived.
Nothing in this subcategory is medical or legal advice, and prescribers reading here consistently say so themselves.
No disagreement from me. Posting only so the question does not look ignored.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
The variance between people here is larger than the effect being discussed.
Post #27 answers the question as asked. The question underneath it is different.
A note on how NHS criteria gets discussed rather than on NHS criteria itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.